Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics2019Vol. 49(6), pp. 664–680
Citations Over TimeTop 1% of 2019 papers
Uday N. Shivaji, C Sharratt, Tom Thomas, Samuel C. Smith, Marietta Iacucci, Gordon W. Moran, Subrata Ghosh, Neeraj Bhala
Abstract
Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.
Related Papers
- → Treatment of ulcerative colitis(2013)47 cited
- → A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis(2018)20 cited
- [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].(2007)
- → P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)(2020)
- → Biologic Therapy of Ulcerative Colitis: Infliximab, Adlimumab, Golimumab(2011)